Oscar Health, Inc. (OSCR) Stock Analysis and Metrics

Oscar Health

NYSE: OSCR

$28.19 ▼ -0.73 (-2.51%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap8.62 Bn

P/E-218.95

P/S1.15

Div. Yield0.00

Total Debt (Qtr)430.88 Mn

Revenue Growth (1y) (Qtr)107,225.50

Add ratio to table…

About

Oscar is a leading healthcare technology company that operates a full stack technology platform and offers health insurance plans under the Affordable Care Act to individuals families and employees. The company focuses on member experience and uses its proprietary technology to drive engagement and deliver high value clinical care. As of December 31 2024 Oscar had approximately 1.68 million effectuated members who were actively enrolled in its plans and had either paid their premium or were within the grace period. In addition to its insurance business Oscar powers providers and payors through its +Oscar platform which provides engagement and recommendation tools. Oscar’s mission is to make a healthier life accessible and affordable for all by combining insurance coverage with innovative digital solutions that reduce friction in the healthcare system. The platform encompasses member data utilization management claims processing billing and benefits administration all built on a cloud native architecture that allows rapid scaling and continuous improvement.

Oscar generates the majority of its revenue from health insurance policy premiums that are collected directly from the Centers for Medicare & Medicaid Services as part of the advanced premium tax credits program and from its members through direct payments. The company also earns revenue from its +Oscar platform by offering services such as Campaign Builder to providers and payors who use the platform for population identification personalized interactions and real time reporting and analytics. Premium revenue is supplemented by risk transfer payments received under the federal risk adjustment program which redistributes funds based on the relative health risk of enrolled members. Oscar’s financial results reflect the combination of premium income risk adjustment and fees from its technology services. For the year ended December 31 2024 premiums earned from the Centers for Medicare & Medicaid Services totaled 9,512.3 million dollars while premiums earned directly from members amounted to 799.3 million dollars.

The company operates through the following segments.

• Oscar's insurance business offers health plans in the individual market under the five metal plan categories defined by the Affordable Care Act namely catastrophic bronze silver gold and platinum. These plans vary in monthly premium and cost sharing between the company and its members. The business designs products that aim to improve health outcomes increase affordability and close gaps in benefits for consumers. It includes programs that target chronic conditions such as diabetes and asthma by offering reduced cost sharing for high value services. The insurance segment relies on risk adjustment calculations that adjust premiums based on the health status of its members relative to the overall state market. It must also meet medical loss ratio requirements set by state and federal regulators which dictate the minimum share of premium revenue that must be spent on clinical care and quality improvement activities. The insurance segment maintains exclusive provider organization EPO plans in most markets and offers health maintenance organization HMO plans in selected areas. It contracts with large health systems and provider groups to create networks that emphasize quality care and cost effectiveness. These contracts may include fee for service arrangements value based incentives or capitated payments depending on the market and the provider.

• The +Oscar platform provides technology solutions to providers and payors through its Campaign Builder product which leverages predictive analytics to identify high value opportunities for engagement and to deliver personalized interactions with real time reporting and analytics to measure outcomes. As of December 31 2024 the platform served nearly 500000 client lives in addition to the approximately 1.68 million members enrolled in Oscar health insurance. The platform supports care management workflows by helping users identify gaps in care automate outreach and track key performance indicators such as hospitalization rates and medication adherence. It also enables providers to integrate Oscar’s data insights into their clinical decision making processes and offers payors a tool to monitor population health and evaluate the effectiveness of intervention programs. The platform also supports integration with electronic health record systems enabling seamless data exchange between Oscar and its provider partners. It allows users to schedule virtual visits send medication reminders and track wellness goals through a unified dashboard.

Oscar occupies a competitive position in the individual health insurance market where it faces competition from national carriers regional carriers Medicaid focused insurers that offer Marketplace products and local Blue Cross plans. The company differentiates itself through its end to end technology platform that enables superior member engagement personalized interactions and efficient care navigation. Its ability to combine insurance operations with data driven insights and tools such as Campaign Builder creates a barrier for competitors that rely on legacy systems. Oscar also benefits from a strong brand reputation for member experience as evidenced by a net promoter score of 66 in the fourth quarter of 2024 which exceeds the industry average. The company has achieved profitability on both an adjusted EBITDA and net income basis in 2024 demonstrating that its technology driven model can generate sustainable earnings while scaling membership across multiple states. Oscar has steadily expanded its geographic footprint by entering new states where it sees favorable regulatory environments and sufficient provider networks. This expansion has been accompanied by improvements in operating efficiency that have lowered the administrative expense ratio and contributed to positive adjusted EBITDA.

Oscar serves individuals families and employees who obtain coverage through the individual market including those who use Individual Coverage Health Reimbursement Arrangements offered by their employers. Through its +Oscar platform the company also provides services to providers and payors who seek to improve member engagement and care management. The company offers coverage in eighteen states as of December 31 2024 with a presence that includes large markets such as Florida Georgia Texas and Ohio as well as smaller states such as Iowa Missouri and Tennessee. Its customer base consists of a diverse set of consumers seeking affordable health care and healthcare organizations looking to leverage technology for better outcomes. Employers who adopt Individual Coverage Health Reimbursement Arrangements can offer their employees a defined contribution to purchase Oscar plans directly through the individual market. Brokers and agents also play a role in enrolling individuals through health insurance exchanges and Oscar compensates them through standard commission structures. The company’s focus on digital acquisition complements these traditional channels by allowing consumers to shop and enroll directly via its website and mobile app.

Investment Thesis

▲ Bull case

Oscar Health's capital position provides a substantial buffer against volatility, with $8.1 billion in cash and investments company-wide and $1.7 billion of capital and surplus in its insurance subsidiaries, including $809 million of excess capital. This strong balance sheet, highlighted by management's emphasis on its resilience, allows the company to absorb potential adverse developments in risk adjustment or claims without compromising operational stability or growth initiatives. The excess capital at subsidiaries specifically indicates regulatory flexibility to pursue strategic investments or acquisitions, such as further expanding the Lucie Health Marketplace, without requiring external financing, thereby reducing dilution risk and enabling faster execution of long-term value-creating opportunities that the market may not be fully pricing in given the company's recent profitability surge.
The Lucie Health Marketplace represents a structural, high-margin growth avenue that management explicitly described as offering higher dollar margins than traditional ACA members and operating without the need to commit risk capital, yet its near-term financial impact was characterized as modest in guidance. This disconnect suggests the market is underestimating the platform's scalability and profitability potential, especially given its carrier-agnostic design, integration of ancillary products like Aflac, and alignment with state-level ICHRA adoption incentives in Mississippi and Illinois. As employer demand for flexible health benefits grows and Oscar leverages its technology to broker network choice across competing carriers, the marketplace could evolve into a significant, recurring revenue stream with superior margins that are not yet reflected in current earnings multiples or full-year EBITDA projections.
Risk adjustment accruals were built conservatively based on pricing assumptions and have not yet incorporated potential favorability from market morbidity trends, as acknowledged by Richard Blackley when he stated the company has "yet to take into account any of the potential favorability" seen in Wakely reports. With management noting that "almost all the signals are pointing towards favorable market morbidity development" and expecting the full-year risk adjustment to normalize to approximately 20% of direct premiums (down from the Q1 24% level), there is a clear pathway for sequential improvement in the medical loss ratio and operating margins throughout 2026. This reacceleration of profitability, driven by a tailwind the market may be overlooking due to focus on the elevated Q1 accrual, positions Oscar to exceed its reaffirmed guidance of $250 million to $450 million in earnings from operations and achieve adjusted EBITDA closer to the higher end of its implied range.
Oscar's technology and AI investments are delivering tangible operational leverage, evidenced by the 60 basis point year-over-year improvement in SG&A ratio to 15.2% despite 53% revenue growth, with management attributing this to "disciplined expense management, fixed-cost leverage, and impact from technology and AI investments." The deployment of tools like the real-time drug pricing feature and bilingual voice agents is not merely incremental but foundational to lowering unit costs as scale increases, creating a self-reinforcing cycle where growth enhances efficiency. This structural cost advantage, combined with the company's focus on high-value clinical care engagement, suggests Oscar can sustain margin expansion even as it navigates market dynamics, a factor the market may be undervaluing by treating AI as a cost center rather than a deflationary force on SG&A that compounds with membership growth.
Membership growth of 56% year-over-year to 3.2 million was driven by above-market enrollment and stable retention, with effectuation rates described as "pretty much as expected to modestly favorable" despite the sunset of enhanced premium tax credits. This resilience in a policy-challenged environment, coupled with management's observation that churn patterns showed "nothing unusual" and payment rates remained consistent, indicates Oscar's value proposition—rooted in technology-driven transparency and member experience—is resonating independently of subsidy tailwinds. The ability to grow organically in a contracting individual market, where competitors have exited, suggests Oscar is gaining share through superior execution, a structural shift that could support sustained above-industry growth and reduce dependency on volatile policy cycles, a narrative not yet fully appreciated in valuation models focused on near-term headwinds.

Oscar Health's capital position provides a substantial buffer against volatility, with $8.1 billion in cash and investments company-wide and $1.7 billion of capital and surplus in its insurance subsidiaries, including $809 million of excess capital. This strong balance sheet, highlighted by management's emphasis on its resilience, allows the company to absorb potential adverse developments in risk adjustment or claims without compromising operational stability or growth initiatives. The excess capital at subsidiaries specifically indicates regulatory flexibility to pursue strategic investments or acquisitions, such as further expanding the Lucie Health Marketplace, without requiring external financing, thereby reducing dilution risk and enabling faster execution of long-term value-creating opportunities that the market may not be fully pricing in given the company's recent profitability surge.
The Lucie Health Marketplace represents a structural, high-margin growth avenue that management explicitly described as offering higher dollar margins than traditional ACA members and operating without the need to commit risk capital, yet its near-term financial impact was characterized as modest in guidance. This disconnect suggests the market is underestimating the platform's scalability and profitability potential, especially given its carrier-agnostic design, integration of ancillary products like Aflac, and alignment with state-level ICHRA adoption incentives in Mississippi and Illinois. As employer demand for flexible health benefits grows and Oscar leverages its technology to broker network choice across competing carriers, the marketplace could evolve into a significant, recurring revenue stream with superior margins that are not yet reflected in current earnings multiples or full-year EBITDA projections.
Risk adjustment accruals were built conservatively based on pricing assumptions and have not yet incorporated potential favorability from market morbidity trends, as acknowledged by Richard Blackley when he stated the company has "yet to take into account any of the potential favorability" seen in Wakely reports. With management noting that "almost all the signals are pointing towards favorable market morbidity development" and expecting the full-year risk adjustment to normalize to approximately 20% of direct premiums (down from the Q1 24% level), there is a clear pathway for sequential improvement in the medical loss ratio and operating margins throughout 2026. This reacceleration of profitability, driven by a tailwind the market may be overlooking due to focus on the elevated Q1 accrual, positions Oscar to exceed its reaffirmed guidance of $250 million to $450 million in earnings from operations and achieve adjusted EBITDA closer to the higher end of its implied range.
Oscar's technology and AI investments are delivering tangible operational leverage, evidenced by the 60 basis point year-over-year improvement in SG&A ratio to 15.2% despite 53% revenue growth, with management attributing this to "disciplined expense management, fixed-cost leverage, and impact from technology and AI investments." The deployment of tools like the real-time drug pricing feature and bilingual voice agents is not merely incremental but foundational to lowering unit costs as scale increases, creating a self-reinforcing cycle where growth enhances efficiency. This structural cost advantage, combined with the company's focus on high-value clinical care engagement, suggests Oscar can sustain margin expansion even as it navigates market dynamics, a factor the market may be undervaluing by treating AI as a cost center rather than a deflationary force on SG&A that compounds with membership growth.
Membership growth of 56% year-over-year to 3.2 million was driven by above-market enrollment and stable retention, with effectuation rates described as "pretty much as expected to modestly favorable" despite the sunset of enhanced premium tax credits. This resilience in a policy-challenged environment, coupled with management's observation that churn patterns showed "nothing unusual" and payment rates remained consistent, indicates Oscar's value proposition—rooted in technology-driven transparency and member experience—is resonating independently of subsidy tailwinds. The ability to grow organically in a contracting individual market, where competitors have exited, suggests Oscar is gaining share through superior execution, a structural shift that could support sustained above-industry growth and reduce dependency on volatile policy cycles, a narrative not yet fully appreciated in valuation models focused on near-term headwinds.

▼ Bear case

Oscar Health's reaffirmed full-year 2026 guidance for earnings from operations ($250 million to $450 million) and adjusted EBITDA (implied ~$365 million to $565 million) appears optimistic given the sequential decline expected from the extraordinary Q1 performance, where net income reached $679 million—the highest in company history. The first quarter benefited from $68 million in favorable prior period development and unusually low medical claims that inflated the risk adjustment payable accrual to 24% of direct premiums, a level management acknowledged is temporary and expects to moderate to approximately 20% for the full year. However, the market may be ignoring the risk that this normalization, combined with the typical seasonal rise in MLR (guided to be highest in Q4 at 83.4%), could compress profitability in the second half of the year, making it difficult to sustain the Q1 earnings run-rate without additional tailwinds that are not yet materializing in the guidance.
The company's reliance on risk adjustment accuracy presents a material unspoken risk, as Richard Blackley admitted that reserves are "still based on the market morbidity assumptions that we went into pricing with" and that they have not adjusted for favorable signals in Wakely reports. While management views this as a potential tailwind, the inverse risk—that market morbidity could worsen relative to pricing assumptions—remains unaddressed and could lead to inadequate reserves, necessitating future earnings hits. This asymmetry is particularly concerning given the CFO's candid admission that they "wait to see more signals before we lean into" favorability, implying a reactive rather than proactive stance, and the market may be underestimating the volatility in risk adjustment outcomes should underlying health trends deviate from expectations, especially as new bronze-plan members increase utilization over time.
Despite highlighting the Lucie Health Marketplace as a strategic innovation, Oscar provided no concrete financial contribution from the platform in its 2026 guidance, with Richard Blackley stating any impact would be "modest" for the year and Mark Bertolini reserving deeper details for the September Investor Day. This lack of near-term visibility, combined with the platform's dependence on employer adoption, broker integration, and network-sharing agreements with competitors like Allstate Health and Aflac, introduces execution risk that the market may be ignoring. The initiative's success hinges on factors outside Oscar's direct control—such as state policy momentum and carrier willingness to participate—and without clear milestones or revenue commitments, the marketplace remains a speculative growth narrative rather than a tangible near-term catalyst, increasing the risk of overvaluation based on unproven future potential.
Oscar's SG&A ratio improvement to 15.2% in Q1, while impressive, may not be sustainable as management acknowledged that the ratio is "likely to be the lowest for us during the course of the year" and expects it to "move sideways to slightly up" through the remainder of 2026, particularly rising in Q4 due to open enrollment efforts. The initial benefit from fixed-cost leverage and AI-driven efficiency gains could be offset by incremental investments in sales, marketing, and technology scaling as the company pursues growth in new markets and product lines like Lucie, suggesting the current efficiency peak may be transient. The market might be ignoring this mean-reversion tendency in administrative costs, especially if revenue growth decelerates from the 53% year-over-year pace, potentially reversing margin expansion and pressuring the ability to meet the upper end of the 15.8%-16.3% SG&A guidance range without compromising growth initiatives.
Membership growth of 56% year-over-year, while strong, occurred against a backdrop of market contraction and the exit of competitors, raising questions about the quality and sustainability of the added lives. Richard Blackley noted that effectuation rates were "pretty much as expected to modestly favorable," but the company benefited from auto-assigned members from a competitor that left the marketplace—a dynamic that may not repeat and could inflate growth metrics artificially. Furthermore, management's emphasis on urban, healthier member demographics introduces concentration risk; if Oscar's book becomes skewed toward lower-risk lives, it could face increasing pressure from risk adjustment mechanisms designed to neutralize such advantages, potentially leading to higher future payables that offset pricing benefits, a structural industry dynamic the market may be overlooking in favor of top-line growth enthusiasm.

Oscar Health's reaffirmed full-year 2026 guidance for earnings from operations ($250 million to $450 million) and adjusted EBITDA (implied ~$365 million to $565 million) appears optimistic given the sequential decline expected from the extraordinary Q1 performance, where net income reached $679 million—the highest in company history. The first quarter benefited from $68 million in favorable prior period development and unusually low medical claims that inflated the risk adjustment payable accrual to 24% of direct premiums, a level management acknowledged is temporary and expects to moderate to approximately 20% for the full year. However, the market may be ignoring the risk that this normalization, combined with the typical seasonal rise in MLR (guided to be highest in Q4 at 83.4%), could compress profitability in the second half of the year, making it difficult to sustain the Q1 earnings run-rate without additional tailwinds that are not yet materializing in the guidance.
The company's reliance on risk adjustment accuracy presents a material unspoken risk, as Richard Blackley admitted that reserves are "still based on the market morbidity assumptions that we went into pricing with" and that they have not adjusted for favorable signals in Wakely reports. While management views this as a potential tailwind, the inverse risk—that market morbidity could worsen relative to pricing assumptions—remains unaddressed and could lead to inadequate reserves, necessitating future earnings hits. This asymmetry is particularly concerning given the CFO's candid admission that they "wait to see more signals before we lean into" favorability, implying a reactive rather than proactive stance, and the market may be underestimating the volatility in risk adjustment outcomes should underlying health trends deviate from expectations, especially as new bronze-plan members increase utilization over time.
Despite highlighting the Lucie Health Marketplace as a strategic innovation, Oscar provided no concrete financial contribution from the platform in its 2026 guidance, with Richard Blackley stating any impact would be "modest" for the year and Mark Bertolini reserving deeper details for the September Investor Day. This lack of near-term visibility, combined with the platform's dependence on employer adoption, broker integration, and network-sharing agreements with competitors like Allstate Health and Aflac, introduces execution risk that the market may be ignoring. The initiative's success hinges on factors outside Oscar's direct control—such as state policy momentum and carrier willingness to participate—and without clear milestones or revenue commitments, the marketplace remains a speculative growth narrative rather than a tangible near-term catalyst, increasing the risk of overvaluation based on unproven future potential.
Oscar's SG&A ratio improvement to 15.2% in Q1, while impressive, may not be sustainable as management acknowledged that the ratio is "likely to be the lowest for us during the course of the year" and expects it to "move sideways to slightly up" through the remainder of 2026, particularly rising in Q4 due to open enrollment efforts. The initial benefit from fixed-cost leverage and AI-driven efficiency gains could be offset by incremental investments in sales, marketing, and technology scaling as the company pursues growth in new markets and product lines like Lucie, suggesting the current efficiency peak may be transient. The market might be ignoring this mean-reversion tendency in administrative costs, especially if revenue growth decelerates from the 53% year-over-year pace, potentially reversing margin expansion and pressuring the ability to meet the upper end of the 15.8%-16.3% SG&A guidance range without compromising growth initiatives.
Membership growth of 56% year-over-year, while strong, occurred against a backdrop of market contraction and the exit of competitors, raising questions about the quality and sustainability of the added lives. Richard Blackley noted that effectuation rates were "pretty much as expected to modestly favorable," but the company benefited from auto-assigned members from a competitor that left the marketplace—a dynamic that may not repeat and could inflate growth metrics artificially. Furthermore, management's emphasis on urban, healthier member demographics introduces concentration risk; if Oscar's book becomes skewed toward lower-risk lives, it could face increasing pressure from risk adjustment mechanisms designed to neutralize such advantages, potentially leading to higher future payables that offset pricing benefits, a structural industry dynamic the market may be overlooking in favor of top-line growth enthusiasm.

Peer Comparison

Companies in the Healthcare Plans

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	UNH	Unitedhealth Group Inc	384.70 Bn	30.02	0.90	77.92 Bn
2	CVS	CVS HEALTH Corp	136.05 Bn	46.86	1.84	63.11 Bn
3	ELV	Elevance Health, Inc.	82.25 Bn	16.64	0.45	31.04 Bn
4	CI	Cigna Group	75.16 Bn	11.50	0.75	30.90 Bn
5	HUM	Humana Inc	47.47 Bn	38.91	0.46	13.99 Bn
6	CNC	Centene Corp	31.35 Bn	-4.86	0.17	16.37 Bn
7	MOH	Molina Healthcare, Inc.	10.44 Bn	54.34	0.24	3.77 Bn
8	OSCR	Oscar Health, Inc.	8.62 Bn	-218.95	1.15	0.43 Bn

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password